News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
587,478 Results
Type
Article (20871)
Company Profile (338)
Press Release (566265)
Multimedia
Podcasts (126)
Webinars (16)
Section
Business (194379)
Career Advice (435)
Deals (29904)
Drug Delivery (68)
Drug Development (71336)
Employer Resources (40)
FDA (12269)
Job Trends (10566)
News (285173)
Policy (22151)
Tag
2025 Best Places to Work (2)
2026 Best Places to Work (2)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (12)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (7)
2027 Genetown Digital (3)
2027 Genetown Elite (3)
2027 Genetown Premier (1)
2027 Genetown Standard (9)
2027 NextGen (8)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (9)
40 Under 40 (2)
Academia (1253)
Accelerated approval (50)
ADA (39)
Adcomms (16)
Allergies (157)
Alliances (41155)
ALS (243)
Alzheimer's disease (1543)
Antibody-drug conjugate (ADC) (652)
Approvals (12985)
Artificial intelligence (675)
ASCO (274)
Autoimmune disease (427)
Automation (43)
Bankruptcy (304)
Belgium (25)
Best Places to Work (8500)
BIO (65)
Biologics (64)
BIOSECURE Act (6)
Biosimilars (199)
BioSpace Insights (91)
Biotechnology (228)
Bispecific (43)
Bladder cancer (189)
Brain cancer (75)
Breast cancer (744)
Cancer (6217)
Cardiovascular disease (447)
Career advice (384)
Career pathing (16)
CAR-T (366)
CDC (11)
CDMO (131)
Celiac Disease (4)
Cell therapy (978)
Cervical cancer (47)
Clinical research (64404)
Collaboration (2240)
Commercialization (48)
Company closure (4)
Compensation (1723)
Complete response letters (78)
COVID-19 (1460)
CRISPR (134)
CRO (1)
C-suite (1330)
Cystic fibrosis (151)
Data (9054)
Denatured (29)
Depression (171)
Dermatology (156)
Diabetes (553)
Diagnostics (4941)
Digital health (49)
Diversity (6)
Diversity, equity & inclusion (12)
Drug discovery (392)
Drug pricing (60)
Drug shortages (6)
Duchenne muscular dystrophy (348)
Earnings (81088)
Editorial (38)
Employer branding (6)
Employer resources (38)
ESMO (378)
Events (104878)
Executive appointments (1052)
Eye disease (11)
FDA (16214)
Fibrodysplasia Ossificans Progressiva (15)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (38)
Funding (1818)
Gene editing (277)
Generative AI (52)
Gene therapy (790)
GLP-1 (730)
Government (1777)
Grass and pollen (4)
Guidances (337)
Healthcare (12099)
Hematology (151)
HIV (77)
Huntington's disease (74)
Idiopathic pulmonary fibrosis (10)
IgA nephropathy (129)
Immunology and inflammation (308)
Immuno-oncology (129)
Indications (247)
Infectious disease (1745)
Inflammatory bowel disease (231)
Inflation Reduction Act (12)
Influenza (100)
Intellectual property (335)
Interviews (58)
IPO (14392)
IRA (13)
Job creations (2423)
Job search strategy (340)
JPM (41)
Kidney cancer (23)
Kidney disease (139)
Labor market (42)
Layoffs (314)
Leadership (22)
Legal (5649)
Licensing (87)
Liver cancer (70)
Longevity (45)
Lung cancer (886)
Lung diease (16)
Lymphoma (430)
Machine learning (50)
Management (10)
Manufacturing (979)
Marketing (29)
MASH (198)
Medical affairs (4)
Medical device (9982)
Medtech (10195)
Mergers & acquisitions (16820)
Metabolic disorders (1352)
mRNA (229)
Multiple sclerosis (183)
Multispecific (6)
NASH (14)
Netherlands (17)
Neurodegenerative disease (485)
Neuropsychiatric disorders (110)
Neuroscience (3248)
Neurotech (3)
NextGen: Class of 2026 (4128)
Non-profit (1521)
Now hiring (48)
Obesity (564)
Opinion (163)
Ovarian cancer (255)
Pain (264)
Pancreatic cancer (371)
Parkinson's disease (404)
Partnered (26)
Patents (658)
Patient advocacy (6)
Patient recruitment (844)
Patient selection (80)
Peanut (58)
People (50024)
Peptides (23)
Pharmaceutical (51)
Pharmacy benefit managers (16)
Phase 1 (21261)
Phase 2 (29061)
Phase 3 (19788)
Pipeline (11440)
Policy (119)
Postmarket research (1891)
Preclinical (9063)
Press Release (52)
Prostate cancer (323)
Psychedelics (84)
Radioligand (3)
Radiopharmaceuticals (379)
Rare diseases (1230)
Real estate (3781)
Recruiting (14)
Regenerative medicine (21)
Regulatory (20014)
Reports (36)
Research institute (1341)
Resumes & cover letters (59)
Rett syndrome (57)
RNA editing (38)
RSV (60)
Schizophrenia (188)
Series A (340)
Series B (232)
Service/supplier (5)
Sickle cell disease (124)
Special edition (23)
Spinal muscular atrophy (149)
Sponsored (25)
Startups (3131)
State (1)
Stem cells (6)
Stomach cancer (10)
Substance use disorders (21)
Supply chain (81)
Switzerland (7)
Tariffs (21)
The Weekly (95)
Vaccines (616)
Venture capital (118)
Weight loss (287)
Wet AMD (5)
Women's health (130)
Worklife (4)
Date
Today (184)
Last 7 days (667)
Last 30 days (2550)
Last 365 days (26296)
2026 (22041)
2025 (25757)
2024 (30030)
2023 (33977)
2022 (43313)
2021 (45731)
2020 (40883)
2019 (29829)
2018 (22460)
2017 (24179)
2016 (22652)
2015 (28865)
2014 (24869)
2013 (20673)
2012 (22487)
2011 (22746)
2010 (22422)
Location
Africa (342)
Alabama (100)
Alaska (3)
Arizona (366)
Arkansas (15)
Asia (29334)
Australia (4521)
California (14973)
Canada (4035)
China (1528)
Colorado (625)
Connecticut (585)
Delaware (408)
Europe (54600)
Florida (2196)
Georgia (454)
Hawaii (4)
Idaho (47)
Illinois (1047)
India (104)
Indiana (477)
Iowa (24)
Japan (622)
Kansas (119)
Kentucky (41)
Louisiana (44)
Maine (38)
Maryland (1560)
Massachusetts (10783)
Michigan (338)
Minnesota (683)
Mississippi (6)
Missouri (99)
Montana (32)
Nebraska (14)
Nevada (154)
New Hampshire (76)
New Jersey (3505)
New Mexico (19)
New York (3676)
North Carolina (1819)
North Dakota (10)
Northern California (7760)
Ohio (377)
Oklahoma (16)
Oregon (37)
Pennsylvania (2886)
Puerto Rico (28)
Rhode Island (41)
South America (528)
South Carolina (86)
South Dakota (1)
Southern California (5985)
Tennessee (158)
Texas (2428)
United States (50536)
Utah (443)
Vermont (1)
Virginia (273)
Washington D.C. (52)
Washington State (1196)
West Virginia (2)
Wisconsin (124)
Wyoming (2)
587,478 Results for "carmot therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Diabetes
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot Therapeutics as well as partner Zealand Pharma.
September 22, 2026
·
2 min read
·
Annalee Armstrong
Obesity
Roche cans one Carmot obesity asset as another shows best-in-class potential
Acmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcomes. Both assets come from the $2.7 billion buy of Carmot Therapeutics.
July 24, 2026
·
2 min read
·
Tristan Manalac
Venture capital
Frazier adds $1.1B+ to small and mid-sized biotech fund
Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for $2.7 billion.
September 11, 2026
·
2 min read
·
Tristan Manalac
Deals
Carmot Therapeutics Announces Completion of Acquisition by Roche
Carmot Therapeutics Inc. today announced that its acquisition by the Roche Group (Roche) has been completed.
January 29, 2024
·
3 min read
Weight loss
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy
Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.
July 26, 2024
·
2 min read
·
Tristan Manalac
Business
Carmot Therapeutics Appoints Charles W. Newton to Board of Directors
Carmot Therapeutics, Inc. today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.
July 19, 2023
·
2 min read
GLP-1
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche’s oral GLP-1 receptor agonist CT-996—obtained in the $2.7 billion acquisition of Carmot Therapeutics—reduced body weight by more than 6% at four weeks versus placebo in a Phase I trial.
July 17, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Roche Sees Early ROI on $2.7B Carmot Buy with Phase I Data for Obesity Candidate
Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study.
May 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
October 13, 2026
·
4 min read
Deals
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
November 20, 2023
·
2 min read
·
Tristan Manalac
1 of 58,748
Next
